RAPP insider transaction filings
Rapport Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen RAPP transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 404 @ $49.90 | EDGAR |
| 2026-08-12 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 14,171 @ $45.97 · Sale (S): 8,370 @ $46.75 · Sale (S): 3,664 @ $46.90 · Sale (S): 19,500 @ $48.04 · Sale (S): 5,794 @ $48.62 | EDGAR |
| 2026-07-29 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 2,203 @ $42.11 · Sale (S): 7 @ $42.73 | EDGAR |
| 2026-07-15 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 5,481 @ $39.72 · Sale (S): 2,729 @ $40.57 | EDGAR |
| 2026-07-01 | 4 | Gault Cheryl — Chief Operating Officer | Sale (S): 1,900 @ $40.09 · Sale (S): 3,792 @ $41.39 · Sale (S): 3,308 @ $42.17 · Sale (S): 1,000 @ $43.15 | EDGAR |
| 2026-07-01 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 7,344 @ $39.77 · Sale (S): 876 @ $40.34 | EDGAR |
| 2026-06-10 | 4 | Young Wendy B. — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Sanchez Ramiro — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Huber Reid M — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Silva Paul M — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | PEREZ ROBERT J — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | HEALY JAMES — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | PAUL STEVEN M — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | MARAGANORE JOHN — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Sale (S): 18,572 @ $40.05 | EDGAR |
| 2026-05-13 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Sale (S): 133,618 @ $40.24 | EDGAR |
| 2026-05-11 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Sale (S): 271,495 @ $40.12 · Sale (S): 5,018 @ $40.31 | EDGAR |
| 2026-04-21 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 20,225 @ $39.99 | EDGAR |
| 2026-04-21 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Sale (S): 426,005 @ $40.32 | EDGAR |
| 2026-04-14 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 500 @ $34.98 · Sale (S): 9,165 @ $34.97 · Sale (S): 10,200 @ $35.08 | EDGAR |
| 2026-04-09 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 360 @ $34.90 | EDGAR |
| 2026-03-31 | 4 | Gault Cheryl — Chief Operating Officer | Sale (S): 7,161 @ $28.04 · Sale (S): 2,839 @ $28.55 | EDGAR |
| 2026-03-26 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 10,115 @ $29.99 | EDGAR |
| 2026-03-09 | 4 | Gault Cheryl — Chief Operating Officer | Sale (S): 2,014 @ $28.93 | EDGAR |
| 2026-02-19 | 4 | Bredt David — Chief Scientific Officer | Sale (S): 900 @ $28.02 · Sale (S): 5,400 @ $28.95 · Sale (S): 2,200 @ $29.59 · Option exercise (M): 6,000 @ $1.80 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 3,552 @ $29.05 · Sale (S): 2,281 @ $29.80 · Sale (S): 2,983 @ $29.04 · Sale (S): 2,100 @ $29.80 | EDGAR |
| 2026-02-04 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Bredt David — Chief Scientific Officer | Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Gault Cheryl — Chief Operating Officer | Grant/award (A): 132,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Sevigny Jeffrey — Chief Medical Officer | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Grant/award (A): 428,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Ignelzi Troy A. — Chief Financial Officer | Grant/award (A): 148,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 5,833 @ $26.12 · Sale (S): 5,083 @ $26.11 | EDGAR |
| 2026-01-16 | 4 | Bredt David — Chief Scientific Officer | Sale (S): 8,300 @ $26.83 · Sale (S): 200 @ $27.40 | EDGAR |
| 2026-01-05 | 4 | Bredt David — Chief Scientific Officer | Grant/award (A): 18,000 · Sale (S): 6,567 @ $30.05 | EDGAR |
| 2026-01-05 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Grant/award (A): 9,000 · Sale (S): 2,840 @ $30.05 | EDGAR |
| 2025-12-18 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 2,441 @ $28.84 · Sale (S): 2,792 @ $30.04 · Sale (S): 600 @ $31.04 · Sale (S): 2,147 @ $28.84 · Sale (S): 2,421 @ $30.04 · Sale (S): 515 @ $31.04 | EDGAR |
| 2025-12-16 | 4 | Bredt David — Chief Scientific Officer | Sale (S): 7,704 @ $29.95 · Sale (S): 796 @ $30.68 | EDGAR |
| 2025-12-01 | 4 | Gault Cheryl — Chief Operating Officer | Option exercise (M): 5,000 @ $1.80 · Sale (S): 5,000 @ $30.10 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Bredt David — Chief Scientific Officer | Sale (S): 3,156 @ $24.84 · Sale (S): 5,344 @ $25.39 | EDGAR |
| 2025-11-18 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 2,777 @ $24.92 · Sale (S): 3,056 @ $25.43 · Sale (S): 2,242 @ $24.91 · Sale (S): 2,841 @ $25.44 | EDGAR |
| 2025-10-16 | 4 | Bredt David — Chief Scientific Officer | Sale (S): 7,418 @ $25.73 · Sale (S): 1,082 @ $26.16 | EDGAR |
| 2025-10-16 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 4,647 @ $25.72 · Sale (S): 1,186 @ $26.14 · Sale (S): 4,328 @ $25.75 · Sale (S): 755 @ $26.17 | EDGAR |
| 2025-09-19 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 39,435 @ $26.30 · Sale (S): 1,400 @ $26.87 · Sale (S): 34,885 @ $26.30 · Sale (S): 700 @ $27.04 | EDGAR |
| 2025-09-17 | 4 | Bredt David — Chief Scientific Officer | Sale (S): 5,098 @ $23.88 · Sale (S): 3,402 @ $24.66 | EDGAR |
| 2025-09-15 | 4 | Huber Reid M — Director | Purchase (P): 20,400 @ $24.48 | EDGAR |
| 2025-09-15 | 4 | PAUL STEVEN M — Director | Purchase (P): 28,284 @ $24.50 · Purchase (P): 13,382 @ $24.97 | EDGAR |
| 2025-09-11 | 4 | Young Wendy B. — Director | Purchase (P): 3,500 @ $22.60 | EDGAR |
| 2025-09-10 | 4 | Gault Cheryl — Chief Operating Officer | Option exercise (M): 5,000 @ $1.80 · Sale (S): 5,000 @ $38.33 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-08-18 | 4 | Bredt David — Chief Scientific Officer | Sale (S): 8,300 @ $14.98 · Sale (S): 200 @ $15.79 | EDGAR |
Recent 8-K events — Rapport Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RAPP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →